Endothelin

Cellular and Molecular Life Sciences

Volumn 68, Issue 2, 2011, Pages 195-203

  Kawanabe, Yoshifumi ^b   Nauli, Surya M ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b NONE

Author keywords

Endothelin; Endothelin receptor; Endothelin signal; Endothelin converting enzymes; Pathophysiology

Indexed keywords

ATRASENTAN; BOSENTAN; CGS 35066; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; ENALAPRIL; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENKEPHALINASE INHIBITOR; KELATORPHAN; MEMBRANE METALLOENDOPEPTIDASE; PACLITAXEL; PREPROENDOTHELIN 1; SITAXSENTAN; TAK 044; TBC 3711; TEZOSENTAN; THIORPHAN; UNCLASSIFIED DRUG; VASOCONSTRICTOR AGENT; ZIBOTENTAN;

ANTIHYPERTENSIVE ACTIVITY; CANCER INHIBITION; CELL GROWTH; CONGESTIVE HEART FAILURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TISSUE LEVEL; ENZYME ISOLATION; ENZYME PURIFICATION; ENZYME STRUCTURE; ESSENTIAL HYPERTENSION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GROWTH INHIBITION; HEART FAILURE; HEART HEMODYNAMICS; HEART HYPERTROPHY; HEART INDEX; HEART RIGHT ATRIUM PRESSURE; HUMAN; HYPERTENSION; HYPOXIA; LUNG VASCULAR RESISTANCE; MEDICAL INFORMATION; NONHUMAN; OVARY CANCER; OXYGEN SATURATION; PATHOPHYSIOLOGY; PHYSICIAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR UPREGULATION; REVIEW; RISK BENEFIT ANALYSIS; SHEAR STRESS; SURVIVAL TIME; TRANSCRIPTION REGULATION; VASOCONSTRICTION; VASODILATATION;

ASPARTIC ACID ENDOPEPTIDASES; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; ENDOTHELINS; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; METALLOENDOPEPTIDASES; OVARIAN NEOPLASMS; RECEPTORS, ENDOTHELIN; VASOCONSTRICTION;

EID: 78651375084     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-010-0518-0     Document Type: Review

References (105)

1. GA Gray DJ Webb 1996 The endothelin system and its potential as a therapeutic target in cardiovascular disease Pharmacol Ther 72 2 109 148 1:CAS:528:DyaK28XmvVClsro%3D 8981573 10.1016/S0163-7258(96)00101-5
2. M Yanagisawa H Kurihara S Kimura Y Tomobe M Kobayashi Y Mitsui Y Yazaki K Goto T Masaki 1988 A novel potent vasoconstrictor peptide produced by vascular endothelial cells Nature 332 6163 411 415 1:CAS:528:DyaL1cXlsVaks78%3D 2451132 10.1038/332411a0
3. RM Kedzierski M Yanagisawa 2001 Endothelin system: the double-edged sword in health and disease Annu Rev Pharmacol Toxicol 41 851 876 1:CAS:528:DC%2BD3MXjsVaqtL0%3D 11264479 10.1146/annurev.pharmtox.41.1.851
4. N Emoto M Yanagisawa 1995 Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum J Biol Chem 270 25 15262 15268 1:CAS:528:DyaK2MXmsFKqtLo%3D 7797512 10.1074/jbc.270.25.15262
5. H Yanagisawa RE Hammer JA Richardson N Emoto SC Williams S Takeda DE Clouthier M Yanagisawa 2000 Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development J Clin Invest 105 10 1373 1382 1:CAS:528:DC%2BD3cXjtlOnsL0%3D 10811845 10.1172/JCI7447
6. AJ Turner LJ Murphy 1996 Molecular pharmacology of endothelin-converting enzymes Biochem Pharmacol 51 2 91 102 1:CAS:528:DyaK28XltFOguw%3D%3D 8615890 10.1016/0006-2952(95)02036-5
7. A Nakano F Kishi K Minami H Wakabayashi Y Nakaya H Kido 1997 Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells J Immunol 159 4 1987 1992 1:CAS:528:DyaK2sXltlGitrs%3D 9257865
8. E Simard D Jin S Takai M Miyazaki I Brochu P D'Orleans-Juste 2009 Chymase-dependent conversion of big endothelin-1 in the mouse in vivo J Pharmacol Exp Ther 328 2 540 548 1:CAS:528:DC%2BD1MXhs1Khu7c%3D 18987301 10.1124/jpet.108.142992
9. J Ortmann PC Nett J Celeiro T Traupe L Tornillo R Hofmann-Lehmann E Haas B Frank LM Terraciano M Barton 2005 Endothelin inhibition delays onset of hyperglycemia and associated vascular injury in type I diabetes: evidence for endothelin release by pancreatic islet beta-cells Biochem Biophys Res Commun 334 2 689 695 1:CAS:528:DC%2BD2MXmsVOnsrw%3D 16009335 10.1016/j.bbrc.2005.06.140
10. K Ohnaka R Takayanagi T Yamauchi H Okazaki M Ohashi F Umeda H Nawata 1990 Identification and characterization of endothelin converting activity in cultured bovine endothelial cells Biochem Biophys Res Commun 168 3 1128 1136 1:CAS:528:DyaK3cXktlGgtL8%3D 2189402 10.1016/0006-291X(90)91146-J
11. T Matsumoto Y Ozawa K Taguchi T Kobayashi K Kamata 2010 Diabetes-associated changes and role of N epsilon-(carboxymethyl)lysine in big ET-1-induced coronary vasoconstriction Peptides 31 2 346 353 1:CAS:528:DC%2BC3cXnt1WmtQ%3D%3D 19962413 10.1016/j.peptides.2009.11.029
12. D Xu N Emoto A Giaid C Slaughter S Kaw D de Wit M Yanagisawa 1994 ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1 Cell 78 3 473 485 1:CAS:528:DyaK2MXkvV2nug%3D%3D 8062389 10.1016/0092-8674(94)90425-1
13. R Takayanagi W Liu T Ito K Ohnaka H Nawata 1998 Big endothelin analogues with inhibitory activity on endothelin-converting enzyme-1 J Cardiovasc Pharmacol 31 Suppl 1 S62 S63 1:CAS:528:DyaK1cXjtFaktb4%3D 9595401 10.1097/00005344-199800001-00020
14. O Valdenaire E Rohrbacher MG Mattei 1995 Organization of the gene encoding the human endothelin-converting enzyme (ECE-1) J Biol Chem 270 50 29794 29798 1:CAS:528:DyaK2MXhtVSitbrP 8530372 10.1074/jbc.270.50.29794
15. S Keynan M Khamaisi R Dahan K Barnes CD Jackson AJ Turner I Raz 2004 Increased expression of endothelin-converting enzyme-1c isoform in response to high glucose levels in endothelial cells J Vasc Res 41 2 131 140 1:CAS:528:DC%2BD2cXjtFKqsrY%3D 15010576 10.1159/000077132
16. LA Lambert AR Whyteside AJ Turner BA Usmani 2008 Isoforms of endothelin-converting enzyme-1 (ECE-1) have opposing effects on prostate cancer cell invasion Br J Cancer 99 7 1114 1120 1:CAS:528:DC%2BD1cXhtFyqt7rN 18781169 10.1038/sj.bjc.6604631
17. J Dupuis CA Goresky A Fournier 1996 Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors J Appl Physiol 81 4 1510 1515 1:CAS:528:DyaK28XmvF2nur4%3D 8904561
18. J Dupuis DJ Stewart P Cernacek G Gosselin 1996 Human pulmonary circulation is an important site for both clearance and production of endothelin-1 Circulation 94 7 1578 1584 1:CAS:528:DyaK28XmsFSntL8%3D 8840847
19. J Goddard DJ Webb 1999 Endothelin receptor antagonists. Promising new agents in the management of cardiovascular disorders Drugs R D 2 1 1 12 1:CAS:528:DyaK1MXmt1Sjtrs%3D 10560541 10.2165/00126839-199902010-00001
20. H Arai S Hori I Aramori H Ohkubo S Nakanishi 1990 Cloning and expression of a cDNA encoding an endothelin receptor Nature 348 6303 730 732 1:CAS:528:DyaK3MXktVaisb0%3D 2175396 10.1038/348730a0
21. T Sakurai M Yanagisawa Y Takuwa H Miyazaki S Kimura K Goto T Masaki 1990 Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor Nature 348 6303 732 735 1:CAS:528:DyaK3MXktVaisbo%3D 2175397 10.1038/348732a0
22. K Hosoda K Nakao A Hiroshi S Suga Y Ogawa M Mukoyama G Shirakami Y Saito S Nakanishi H Imura 1991 Cloning and expression of human endothelin-1 receptor cDNA FEBS Lett 287 1-2 23 26 1:CAS:528:DyaK38XltVGmt7k%3D 1652463 10.1016/0014-5793(91)80007-P
23. AP Davenport G O'Reilly P Molenaar JJ Maguire RE Kuc A Sharkey CR Bacon A Ferro 1993 Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: evidence for expression of ETB receptors in human vascular smooth muscle J Cardiovasc Pharmacol 22 Suppl 8 S22 S25 1:CAS:528:DyaK2cXntVWrtg%3D%3D 7509950 10.1097/00005344-199322008-00008
24. R Takayanagi K Kitazumi C Takasaki K Ohnaka S Aimoto K Tasaka M Ohashi H Nawata 1991 Presence of non-selective type of endothelin receptor on vascular endothelium and its linkage to vasodilation FEBS Lett 282 1 103 106 1:CAS:528:DyaK3MXisVWgt7o%3D 1851107 10.1016/0014-5793(91)80454-B
25. TF Luscher M Barton 2000 Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs Circulation 102 19 2434 2440 1:CAS:528:DC%2BD3cXptVSjtbg%3D 11067800
26. TF Luscher 1990 Endothelium-derived vasoactive factors and regulation of vascular tone in human blood vessels Lung 168 Suppl 27 34 2166886 10.1007/BF02718110
27. KK Griendling T Tsuda RW Alexander 1989 Endothelin stimulates diacylglycerol accumulation and activates protein kinase C in cultured vascular smooth muscle cells J Biol Chem 264 14 8237 8240 1:CAS:528:DyaL1MXktlCitrg%3D 2656676
28. Y Takuwa Y Kasuya N Takuwa M Kudo M Yanagisawa K Goto T Masaki K Yamashita 1990 Endothelin receptor is coupled to phospholipase C via a pertussis toxin-insensitive guanine nucleotide-binding regulatory protein in vascular smooth muscle cells J Clin Invest 85 3 653 658 1:CAS:528:DyaK3cXhsFanur0%3D 2155922 10.1172/JCI114488
29. S Eguchi Y Hirata T Imai F Marumo 1993 Endothelin receptor subtypes are coupled to adenylate cyclase via different guanyl nucleotide-binding proteins in vasculature Endocrinology 132 2 524 529 1:CAS:528:DyaK3sXhsVSltLs%3D 7678793 10.1210/en.132.2.524
30. Eguchi S, Hirata Y, Marumo F 1993 Endothelin subtype B receptors are coupled to adenylate cyclase via inhibitory G protein in cultured bovine endothelial cells. J Cardiovasc Pharmacol 22 (Suppl) 8: S161-3
31. Y Kawanabe Y Okamoto N Hashimoto T Masaki 2004 Molecular mechanisms for activation of voltage-independent Ca2 + channels by endothelin-1/endothelin-A receptors J Cardiovasc Pharmacol 44 Suppl 1 S219 S223 1:CAS:528: DC%2BD2MXjvVCltA%3D%3D 15838284 10.1097/01.fjc.0000166252.66486.06
32. A Gohla S Offermanns TM Wilkie G Schultz 1999 Differential involvement of Galpha12 and Galpha13 in receptor-mediated stress fiber formation J Biol Chem 274 25 17901 17907 1:CAS:528:DyaK1MXktVylsLg%3D 10364236 10.1074/jbc.274.25. 17901
33. I Aramori S Nakanishi 1992 Coupling of two endothelin receptor subtypes to differing signal transduction in transfected Chinese hamster ovary cells J Biol Chem 267 18 12468 12474 1:CAS:528:DyaK38XkvVCiur8%3D 1319997
34. I Aramori H Nirei M Shoubo K Sogabe K Nakamura H Kojo Y Notsu T Ono S Nakanishi 1993 Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected Chinese hamster ovary cells Mol Pharmacol 43 2 127 131 1:CAS:528:DyaK3sXit1Knurs%3D 8429819
35. Y Kawanabe Y Okamoto S Miwa N Hashimoto T Masaki 2002 Molecular mechanisms for the activation of voltage-independent Ca2 + channels by endothelin-1 in Chinese hamster ovary cells stably expressing human endothelin(A) receptors Mol Pharmacol 62 1 75 80 1:CAS:528:DC%2BD38Xlt1Kqtb8%3D 12065757 10.1124/mol.62.1.75
36. T Masaki S Miwa T Sawamura H Ninomiya Y Okamoto 1999 Subcellular mechanisms of endothelin action in vascular system Eur J Pharmacol 375 1-3 133 138 1:CAS:528:DyaK1MXks1CrsrY%3D 10443571 10.1016/S0014-2999(99)00252-6
37. M Takigawa T Sakurai Y Kasuya Y Abe T Masaki K Goto 1995 Molecular identification of guanine-nucleotide-binding regulatory proteins which couple to endothelin receptors Eur J Biochem 228 1 102 108 1:CAS:528:DyaK2MXjvFKksLg%3D 7882989 10.1111/j.1432-1033.1995.tb20236.x
38. Y Kawanabe Y Okamoto K Nozaki N Hashimoto S Miwa T Masaki 2002 Molecular mechanism for endothelin-1-induced stress-fiber formation: analysis of G proteins using a mutant endothelin(A) receptor Mol Pharmacol 61 2 277 284 1:CAS:528:DC%2BD38Xos1Oiuw%3D%3D 11809851 10.1124/mol.61.2.277
39. A Giaid M Yanagisawa D Langleben RP Michel R Levy H Shennib S Kimura T Masaki WP Duguid DJ Stewart 1993 Expression of endothelin-1 in the lungs of patients with pulmonary hypertension N Engl J Med 328 24 1732 1739 1:STN:280:DyaK3s3mvVensA%3D%3D 8497283 10.1056/NEJM199306173282402
40. R Corder M Carrier N Khan P Klemm JR Vane 1995 Cytokine regulation of endothelin-1 release from bovine aortic endothelial cells J Cardiovasc Pharmacol 26 Suppl 3 S56 S58 1:CAS:528:DyaK2MXps1Kiurs%3D 8587467
41. M Nootens E Kaufmann T Rector C Toher D Judd GS Francis S Rich 1995 Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels J Am Coll Cardiol 26 7 1581 1585 1:CAS:528:DyaK28XlvFCquw%3D%3D 7594089 10.1016/0735-1097(95)00399-1
42. DJ Stewart RD Levy P Cernacek D Langleben 1991 Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 114 6 464 469 1:STN:280:DyaK3M7js1SmsA%3D%3D 1994793
43. M Bauer H Wilkens F Langer SO Schneider H Lausberg HJ Schafers 2002 Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension Circulation 105 9 1034 1036 1:CAS:528: DC%2BD38XislWit7w%3D 11877350 10.1161/hc0902.105719
44. H Takahashi S Soma M Muramatsu M Oka H Ienaga Y Fukuchi 2001 Discrepant distribution of big endothelin (ET)-1 and ET receptors in the pulmonary artery Eur Respir J 18 1 5 14 1:CAS:528:DC%2BD3MXmtlGhu7s%3D 11510805 10.1183/09031936.01.00075501
45. RN Channick G Simonneau O Sitbon IM Robbins A Frost VF Tapson DB Badesch S Roux M Rainisio F Bodin LJ Rubin 2001 Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study Lancet 358 9288 1119 1123 1:CAS:528: DC%2BD3MXntlOrurs%3D 11597664 10.1016/S0140-6736(01)06250-X
46. LJ Rubin DB Badesch RJ Barst N Galie CM Black A Keogh T Pulido A Frost S Roux I Leconte M Landzberg G Simonneau 2002 Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 12 896 903 1:CAS:528:DC%2BD38Xit1ekur0%3D 11907289 10.1056/NEJMoa012212
47. RJ Barst D Langleben A Frost EM Horn R Oudiz S Shapiro V McLaughlin N Hill VF Tapson IM Robbins D Zwicke B Duncan RA Dixon LR Frumkin 2004 Sitaxentan therapy for pulmonary arterial hypertension Am J Respir Crit Care Med 169 4 441 447 14630619 10.1164/rccm.200307-957OC
48. RJ Cody GJ Haas PF Binkley Q Capers R Kelley 1992 Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure Circulation 85 2 504 509 1:STN:280:DyaK387js1Giuw%3D%3D 1735147
49. R Pacher B Stanek M Hulsmann J Koller-Strametz R Berger M Schuller E Hartter E Ogris B Frey G Heinz G Maurer 1996 Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure J Am Coll Cardiol 27 3 633 641 1:STN:280: DyaK283gsVyitw%3D%3D 8606275 10.1016/0735-1097(95)00520-X
50. M Hulsmann B Stanek B Frey B Sturm D Putz T Kos R Berger W Woloszczuk D Putz T Kos R Berger W Woloszczuk G Maurer R Pacher 1998 Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure J Am Coll Cardiol 32 6 1695 1700 1:STN:280:DyaK1M%2FjslyqsA%3D%3D 9822098 10.1016/S0735-1097(98)00437-9
51. K Ponicke M Vogelsang M Heinroth K Becker O Zolk M Bohm HR Zerkowski OE Brodde 1998 Endothelin receptors in the failing and nonfailing human heart Circulation 97 8 744 751 1:CAS:528:DyaK1cXhslCjtLo%3D 9498537
52. O Zolk J Quattek G Sitzler T Schrader G Nickenig P Schnabel K Shimada M Takahashi M Bohm 1999 Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure Circulation 99 16 2118 2123 1:CAS:528:DyaK1MXjtVOhur0%3D 10217651
53. PJ Cowburn JG Cleland JD McArthur MR MacLean JJ McMurray HJ Dargie 1998 Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure Lancet 352 9123 201 202 1:CAS:528:DyaK1cXlt1altbY%3D 9683214 10.1016/S0140-6736(05)77807-7
54. W Kiowski G Sutsch P Hunziker P Muller J Kim E Oechslin R Schmitt R Jones O Bertel 1995 Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure Lancet 346 8977 732 736 1:STN:280:DyaK2Mzoslyhug%3D%3D 7658874 10.1016/S0140-6736(95)91504-4
55. LE Spieker V Mitrovic G Noll R Pacher MR Schulze J Muntwyler C Schalcher W Kiowski TF Luscher 2000 Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators J Am Coll Cardiol 35 7 1745 1752 1:CAS:528: DC%2BD3cXktlGlt7c%3D 10841220 10.1016/S0735-1097(00)00649-5
56. G Torre-Amione JB Young WS Colucci BS Lewis C Pratt G Cotter K Stangl U Elkayam JR Teerlink A Frey M Rainisio I Kobrin 2003 Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure J Am Coll Cardiol 42 1 140 147 1:CAS:528:DC%2BD3sXmtVOisrk%3D 12849674 10.1016/S0735-1097(03)00556-4
57. G Cotter W Kiowski E Kaluski I Kobrin O Milovanov A Marmor J Jafari L Reisin R Krakover Z Vered A Caspi 2001 Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure Eur J Heart Fail 3 4 457 461 1:CAS:528: DC%2BD3MXntVSgt7k%3D 11511432 10.1016/S1388-9842(01)00168-4
58. E Kaluski I Kobrin R Zimlichman A Marmor O Krakov O Milo A Frey S Kaplan R Krakover A Caspi Z Vered G Cotter 2003 RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study J Am Coll Cardiol 41 2 204 210 1:CAS:528:DC%2BD3sXht1Srs78%3D 12535809 10.1016/S0735-1097(02)02708-0
59. CM O'Connor WA Gattis KF Adams Jr V Hasselblad B Chandler A Frey I Kobrin M Rainisio MR Shah J Teerlink M Gheorghiade 2003 Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4) J Am Coll Cardiol 41 9 1452 1457 12742280 10.1016/S0735-1097(03)00194-3 1:CAS:528:DC%2BD3sXksVWju7g%3D
60. CM O'Connor WA Gattis KF Adams Jr MR Shah I Kobrin A Frey M Gheorghiade 2002 Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4) Am Heart J 144 4 583 588 12360152
61. C Schalcher G Cotter L Reisin O Bertel I Kobrin TT Guyene W Kiowski 2001 The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure Am Heart J 142 2 340 349 1:CAS:528:DC%2BD3MXmsV2lu7o%3D 11479476 10.1067/mhj.2001.116760
62. G Torre-Amione JB Durand S Nagueh MT Vooletich I Kobrin C Pratt 2001 A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure Chest 120 2 460 466 1:CAS:528:DC%2BD3MXmsF2rtb8%3D 11502644 10.1378/chest.120.2.460
63. G Torre-Amione JB Young J Durand B Bozkurt DL Mann I Kobrin CM Pratt 2001 Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure Circulation 103 7 973 980 1:CAS:528:DC%2BD3MXit1Cqsr0%3D 11181472
64. PR Kalra JC Moon AJ Coats 2002 Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 85 2-3 195 197 12208583 10.1016/S0167-5273(02)00182-1
65. P Mylona JG Cleland 1999 Update of REACH-1 and MERIT-HF clinical trials in heart failure Cardio.net Editorial Team Eur J Heart Fail 1 2 197 200 1:STN:280:DC%2BD3cvgtlKjsw%3D%3D 10937931 10.1016/S1388-9842(99)00022-7
66. S Iwasa J Fan T Miyauchi T Watanabe 2001 Blockade of endothelin receptors reduces diet-induced hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice Pathobiology 69 1 1 10 1:CAS:528:DC%2BD3MXns1ait7w%3D 11641611 10.1159/000048751
67. K Yokokawa H Tahara M Kohno K Murakawa K Yasunari K Nakagawa T Hamada S Otani M Yanagisawa T Takeda 1991 Hypertension associated with endothelin-secreting malignant hemangioendothelioma Ann Intern Med 114 3 213 215 1:STN:280:DyaK3M%2FotlagsQ%3D%3D 1984746
68. M Barton S Shaw LV d'Uscio P Moreau TF Luscher 1997 Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation Biochem Biophys Res Commun 238 3 861 865 1:CAS:528:DyaK2sXmsFCnsL8%3D 9325182 10.1006/bbrc.1997.7394
69. Schiffrin EL (2001) Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 14(6 Pt 2):83S-89S
70. M Barton 2008 Reversal of proteinuric renal disease and the emerging role of endothelin Nat Clin Pract Nephrol 4 9 490 501 1:CAS:528:DC%2BD1cXhtVamtr3E 18648345 10.1038/ncpneph0891
71. G Caligiuri B Levy J Pernow P Thoren GK Hansson 1999 Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic mice Proc Natl Acad Sci USA 96 12 6920 6924 1:CAS:528:DyaK1MXks1Wkt78%3D 10359814 10.1073/pnas.96.12.6920
72. M Barton 2000 Endothelial dysfunction and atherosclerosis: endothelin receptor antagonists as novel therapeutics Curr Hypertens Rep 2 1 84 91 1:STN:280:DC%2BD3M%2FhsFagtw%3D%3D 10981133 10.1007/s11906-000-0064-5
73. S Taddei A Virdis L Ghiadoni I Sudano M Notari A Salvetti 1999 Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension Circulation 100 16 1680 1683 1:CAS:528:DyaK1MXntlSqsbg%3D 10525485
74. AV Agapitov WG Haynes 2002 Role of endothelin in cardiovascular disease J Renin Angiotensin Aldosterone Sys 3 1 1 15 1:CAS:528:DC%2BD38Xjs1Knu7c%3D 10.3317/jraas.2002.001
75. P Moreau LV d'Uscio S Shaw H Takase M Barton TF Luscher 1997 Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist Circulation 96 5 1593 1597 1:CAS:528: DyaK2sXmtFeisLs%3D 9315552
76. Ohuchi T, Kuwaki T, Ling GY, Dewit D, Ju KH, Onodera M, Cao WH, Yanagisawa M, Kumada M (1999) Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice. Am J Physiol 276(4 Pt 2):R1071-7
77. Strachan FE, Spratt JC, Wilkinson IB, Johnston NR, Gray GA, Webb DJ (1999) Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 33(1 Pt 2):581-585
78. WG Haynes CJ Ferro KP O'Kane D Somerville CC Lomax DJ Webb 1996 Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans Circulation 93 10 1860 1870 1:CAS:528:DyaK28Xjs1Sku70%3D 8635265
79. WG Haynes DJ Webb 1994 Contribution of endogenous generation of endothelin-1 to basal vascular tone Lancet 344 8926 852 854 1:STN:280: DyaK2czns1Gnsg%3D%3D 7916401 10.1016/S0140-6736(94)92827-4
80. H Krum RJ Viskoper Y Lacourciere M Budde V Charlon 1998 The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan hypertension Investigators N Engl J Med 338 12 784 790 1:CAS:528:DyaK1cXitlChtbs%3D 9504938 10.1056/NEJM199803193381202
81. J Goddard NR Johnston MF Hand AD Cumming TJ Rabelink AJ Rankin DJ Webb 2004 Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade Circulation 109 9 1186 1193 1:CAS:528:DC%2BD2cXhs12kt7w%3D 14981006 10.1161/01.CIR.0000118499.69469.51
82. J Goddard C Eckhart NR Johnston AD Cumming AJ Rankin DJ Webb 2004 Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism J Am Soc Nephrol 15 10 2601 2610 1:CAS:528:DC%2BD2cXnslOnu70%3D 15466264 10.1097/01.ASN.0000141313.84470.4B
83. N Dhaun J Goddard DJ Webb 2006 The endothelin system and its antagonism in chronic kidney disease J Am Soc Nephrol 17 4 943 955 1:CAS:528: DC%2BD28XjvFSqsLc%3D 16540557 10.1681/ASN.2005121256
84. N Dhaun IM Macintyre V Melville P Lilitkarntakul NR Johnston J Goddard DJ Webb 2009 Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease Hypertension 54 1 113 119 1:CAS:528:DC%2BD1MXntVyrtL0%3D 19506099 10.1161/HYPERTENSIONAHA.109.132670
85. A Bhalla S Haque I Taylor M Winslet M Loizidou 2009 Endothelin receptor antagonism and cancer Eur J Clin Invest 39 Suppl 2 74 77 1:CAS:528: DC%2BD1MXmvVyiurY%3D 19335749 10.1111/j.1365-2362.2009.02123.x
86. A Bagnato KJ Catt 1998 Endothelins as autocrine regulators of tumor cell growth Trends Endocrinol Metab 9 9 378 383 1:CAS:528:DyaK1cXnsVKnsbw%3D 18406309 10.1016/S1043-2760(98)00094-0
87. A Bagnato D Salani V Di Castro JR Wu-Wong R Tecce MR Nicotra A Venuti PG Natali 1999 Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth Cancer Res 59 3 720 727 1:CAS:528:DyaK1MXhtFSisbo%3D 9973223
88. A Bagnato R Tecce C Moretti V Di Castro D Spergel KJ Catt 1995 Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells Clin Cancer Res 1 9 1059 1066 1:CAS:528:DyaK2MXoslSmtL4%3D 9816080
89. L Rosano F Spinella V Di Castro MR Nicotra S Dedhar AG de Herreros PG Natali A Bagnato 2005 Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells Cancer Res 65 24 11649 11657 1:CAS:528: DC%2BD2MXhtlWiu7rE 16357176 10.1158/0008-5472.CAN-05-2123
90. D Salani V Di Castro MR Nicotra L Rosano R Tecce A Venuti PG Natali A Bagnato 2000 Role of endothelin-1 in neovascularization of ovarian carcinoma Am J Pathol 157 5 1537 1547 1:CAS:528:DC%2BD3cXosFyhsrs%3D 11073813
91. AA Jazaeri CS Awtrey GV Chandramouli YE Chuang J Khan C Sotiriou O Aprelikova CJ Yee KK Zorn MJ Birrer JC Barrett J Boyd 2005 Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers Clin Cancer Res 11 17 6300 6310 1:CAS:528:DC%2BD2MXpslansLY%3D 16144934 10.1158/1078-0432.CCR-04-2682
92. I Komuro H Kurihara T Sugiyama M Yoshizumi F Takaku Y Yazaki 1988 Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells FEBS Lett 238 2 249 252 1:CAS:528:DyaL1cXmtVGksrY%3D 3139457 10.1016/0014-5793(88)80489-7
93. F Vacca A Bagnato KJ Catt R Tecce 2000 Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells Cancer Res 60 18 5310 5317 1:CAS:528: DC%2BD3cXntValsrw%3D 11016663
94. A Pedram M Razandi AJ Evinger E Lee ER Levin 2009 Estrogen inhibits ATR signaling to cell cycle checkpoints and DNA repair Mol Biol Cell 20 14 3374 3389 1:CAS:528:DC%2BD1MXhsVClt7%2FN 19477925 10.1091/mbc.E09-01-0085
95. F Spinella L Rosano G Elia V Di Castro PG Natali A Bagnato 2004 Endothelin-1 stimulates cyclooxygenase-2 expression in ovarian cancer cells through multiple signaling pathways: evidence for involvement of transactivation of the epidermal growth factor receptor J Cardiovasc Pharmacol 44 Suppl 1 S140 S143 1:CAS:528:DC%2BD2MXjvVCnug%3D%3D 15838264 10.1097/01.fjc.0000166255.12229. 0d
96. F Spinella L Rosano S Decandia V Di Castro A Albini G Elia PG Natali A Bagnato 2006 Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target Exp Biol Med (Maywood) 231 6 1123 1127 1:CAS:528:DC%2BD28Xlt1ertb0%3D
97. A Jimeno M Carducci 2005 Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer Expert Rev Anticancer Ther 5 3 419 427 1:CAS:528:DC%2BD2MXmtF2it7g%3D 16001950 10.1586/14737140.5.3.419
98. L Rosano V Di Castro F Spinella S Decandia PG Natali A Bagnato 2006 ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation Exp Biol Med (Maywood) 231 6 1132 1135 1:CAS:528: DC%2BD28Xlt1ertbs%3D
99. R Warren G Liu 2008 ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer Expert Opin Investig Drugs 17 8 1237 1245 1:CAS:528:DC%2BD1cXos1Chs7o%3D 18616419 10.1517/13543784.17.8.1237
100. JW Growcott 2009 Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054 Anticancer Drugs 20 2 83 88 1:CAS:528:DC%2BD1MXhvVSitLs%3D 19065106 10.1097/CAD.0b013e328320791c
101. L Rosano R Cianfrocca S Masi F Spinella V Di Castro A Biroccio E Salvati MR Nicotra PG Natali A Bagnato 2009 Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis Proc Natl Acad Sci USA 106 8 2806 2811 1:CAS:528:DC%2BD1MXislaht70%3D 19202075 10.1073/pnas.0807158106
102. L Rosano V Di Castro F Spinella MR Nicotra PG Natali A Bagnato 2007 ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo Mol Cancer Ther 6 7 2003 2011 1:CAS:528:DC%2BD2sXnsV2jsrg%3D 17620430 10.1158/1535-7163.MCT-07-0151
103. L Rosano F Spinella V Di Castro PG Natali A Bagnato 2004 Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan J Cardiovasc Pharmacol 44 Suppl 1 S132 S135 1:CAS:528:DC%2BD2MXjvVCntA%3D%3D 15838262 10.1097/01.fjc.0000166259.96980.6a
104. L Rosano F Spinella D Salani V Di Castro A Venuti MR Nicotra PG Natali A Bagnato 2003 Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma Cancer Res 63 10 2447 2453 1:CAS:528:DC%2BD3sXjslehsLc%3D 12750265
105. M Smollich P Wulfing 2007 The endothelin axis: a novel target for pharmacotherapy of female malignancies Curr Vasc Pharmacol 5 3 239 248 1:CAS:528:DC%2BD2sXmsFehur8%3D 17627567 10.2174/157016107781024082